Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shitong Xie

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Applied Health Economics and Health Policy|December 13, 2024
Quality-Adjusted Life Expectancy Norms Based on the EQ-5D-5L and SF-6Dv2 for ChinaShitong Xie, Xiaoning He, Weihua Guo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 4, 2024
Understanding Canadian stakeholders' views on measuring and valuing health for children and adolescents: a qualitative studyFeng Xie, Shitong Xie, Eleanor Pullenayegum, et al.
Health Economics Review|June 6, 2024
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in ChinaShitong Xie, Yanan Sheng, Ling-Hsiang Chuang, et al.
The Patient|April 20, 2024
Evaluating the Preferences and Willingness-to-Pay for Oral Antidiabetic Drugs Among Patients with Type 2 Diabetes Mellitus in China: A Discrete Choice ExperimentLing-Hsiang Chuang, Huanlan Zhang, Tianqi Hong, et al.
Social Science & Medicine (1982)|July 2, 2026
Health inequality aversion in China: Public and decision-maker viewsXiaoning He, Yuhang Xin, Shitong Xie, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 10, 2026
Reply to "Cost-of-illness of myelodysplastic syndromes in Italy. A reply to Tse et al."Preston Tse, Shitong Xie, Jiajun Yan, et al.
Journal of Evidence-Based Medicine|September 10, 2025
Burden of Myelodysplastic Syndromes: A Literature Review of Epidemiological and Humanistic AspectsShitong Xie, Jiajun Yan, Preston Tse, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 23, 2025
Burden of myelodysplastic syndromes: a systematic literature review of economic burdenPreston Tse, Shitong Xie, Jiajun Yan, et al.
The Lancet. Psychiatry|March 20, 2022
Confidence of evidence should be considered in ranking of treatments in the network meta-analysisShitong Xie, Ying Zhu, Xiaoqin Wang, et al.
Health and Quality of Life Outcomes|June 16, 2022
Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health surveyShitong Xie, Dingyao Wang, Jing Wu, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Applied Health Economics and Health Policy|December 13, 2024
Quality-Adjusted Life Expectancy Norms Based on the EQ-5D-5L and SF-6Dv2 for ChinaShitong Xie, Xiaoning He, Weihua Guo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 4, 2024
Understanding Canadian stakeholders' views on measuring and valuing health for children and adolescents: a qualitative studyFeng Xie, Shitong Xie, Eleanor Pullenayegum, et al.
Health Economics Review|June 6, 2024
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in ChinaShitong Xie, Yanan Sheng, Ling-Hsiang Chuang, et al.
The Patient|April 20, 2024
Evaluating the Preferences and Willingness-to-Pay for Oral Antidiabetic Drugs Among Patients with Type 2 Diabetes Mellitus in China: A Discrete Choice ExperimentLing-Hsiang Chuang, Huanlan Zhang, Tianqi Hong, et al.
Social Science & Medicine (1982)|July 2, 2026
Health inequality aversion in China: Public and decision-maker viewsXiaoning He, Yuhang Xin, Shitong Xie, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 10, 2026
Reply to "Cost-of-illness of myelodysplastic syndromes in Italy. A reply to Tse et al."Preston Tse, Shitong Xie, Jiajun Yan, et al.
Journal of Evidence-Based Medicine|September 10, 2025
Burden of Myelodysplastic Syndromes: A Literature Review of Epidemiological and Humanistic AspectsShitong Xie, Jiajun Yan, Preston Tse, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 23, 2025
Burden of myelodysplastic syndromes: a systematic literature review of economic burdenPreston Tse, Shitong Xie, Jiajun Yan, et al.
The Lancet. Psychiatry|March 20, 2022
Confidence of evidence should be considered in ranking of treatments in the network meta-analysisShitong Xie, Ying Zhu, Xiaoqin Wang, et al.
Health and Quality of Life Outcomes|June 16, 2022
Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health surveyShitong Xie, Dingyao Wang, Jing Wu, et al.
Pageof 6